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A B S T R A C T   
The etiology of myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is unknown, but involvement of 
the immune system is one of the proposed underlying mechanisms. Human leukocyte antigen (HLA) associations 
are hallmarks of immune-mediated and autoimmune diseases. We have previously performed high resolution 
HLA genotyping and detected associations between ME/CFS and certain HLA class I and class II alleles. However, 
the HLA complex harbors numerous genes of immunological importance, and there is extensive and complex 
linkage disequilibrium across the region. In the current study, we aimed to fine map the association signals in the 
HLA complex by genotyping five additional classical HLA loci and 5,342 SNPs in 427 Norwegian ME/CFS pa-
tients, diagnosed according to the Canadian Consensus Criteria, and 480 healthy Norwegian controls. SNP as-
sociation analysis revealed two distinct and independent association signals (p ≤ 0.001) tagged by rs4711249 in 
the HLA class I region and rs9275582 in the HLA class II region. Furthermore, the primary association signal in 
the HLA class II region was located within the HLA-DQ gene region, most likely due to HLA-DQB1, particularly 
the amino acid position 57 (aspartic acid/alanine) in the peptide binding groove, or an intergenic SNP upstream 
of HLA-DQB1. In the HLA class I region, the putative causal locus might map outside the classical HLA genes as 
the association signal spans several genes (DDR1, GTF2H4, VARS2, SFTA2 and DPCR1) with expression levels 
influenced by the ME/CFS associated SNP genotype. Taken together, our results implicate the involvement of the 
MHC, and in particular the HLA-DQB1 gene, in ME/CFS. These findings should be replicated in larger cohorts, 
particularly to verify the putative involvement of HLA-DQB1, a gene important for antigen-presentation to T cells 
and known to harbor alleles providing the largest risk for well–established autoimmune diseases.   
1. Introduction 
Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is 
a disease of unknown etiology and pathogenesis resulting in a variety of 
symptoms like post exertional malaise (PEM), brain fog, fatigue and 
pain. No drug interventions are currently available, thus, emphasizing 
* Corresponding authors at: Department of Medical Genetics, Oslo University Hospital, PO box 4956 Nydalen, 0424 Oslo, Norway. 
E-mail addresses: riad.hajdarevic@medisin.uio.no (R. Hajdarevic), m.k.viken@ous-research.no (M.K. Viken).   
1 Joint last authors. 
Contents lists available at ScienceDirect 
Brain Behavior and Immunity 
journal homepage: www.elsevier.com/locate/ybrbi 
https://doi.org/10.1016/j.bbi.2021.08.219 
Received 23 June 2021; Received in revised form 4 August 2021; Accepted 9 August 2021   
Brain Behavior and Immunity 98 (2021) 101–109
102
the need for more research. Comorbidity of ME/CFS with various 
autoimmune diseases is observed in a substantial number of patients, 
likewise for fibromyalgia and postural orthostatic tachycardia syndrome 
(POTS) (Sotzny et al., 2018). The presence of hereditary components in 
ME/CFS susceptibility is suggested by an increased disease risk in first 
degree relatives (Lawrie and Pelosi, 1995; Buchwald, 2001; Carruthers 
et al., 2003; Albright et al., 2011). 
An increasing amount of evidence points towards an immune and/or 
metabolically mediated cause for ME/CFS (Sepúlveda et al., 2019; 
Smith, 2005; Sotzny et al., 2018). Immune alterations, similar to those of 
established autoimmune diseases (Sotzny et al., 2018), as well as onset 
after viral exposure to e.g Epstein-Barr-virus or human papillomavirus, T 
cell alterations and presence of autoantibodies, have all been suggested 
in ME/CFS (Sepúlveda et al., 2019; Sotzny et al., 2018; Rasa et al., 2018; 
Feiring et al., 2017). The major genetic determinants for most autoim-
mune diseases are the human leukocyte antigen (HLA) genes within the 
Major Histocompatibility complex (MHC) (Trowsdale and Knight, 
2013). This genetic region stretches over 3.7 million base pairs on 
chromosome 6p21 and consists of>250 genes. The region occupies 
approximately 0.13% of the human genome but contains ~0.5% (>150) 
of all protein coding genes (Trowsdale and Knight, 2013). >60% of these 
genes encode immunologically important proteins (Trowsdale and 
Knight, 2013). The extended MHC (7.5 Mb) is typically divided into the 
extended class I, class I, class III, class II and extended class II subregions, 
with the classical HLA genes encoding for antigen presenting molecules 
located in the class I and II subregions. These genes harbor variants 
associated with both susceptibility and protection for numerous auto-
immune diseases (Trowsdale and Knight, 2013), however, the hyper- 
polymorphic properties and extensive linkage disequilibrium (LD) in 
the region can make it difficult to pinpoint causal genetic variants 
(Thorsby and Lie, 2005). 
In the case of ME/CFS, investigation by our group and others have 
previously identified associations with specific HLA alleles (Keller, 
1994; Smith, 2005; Lande, 2020). The studies that investigated the 
involvement of MHC in ME/CFS are inconsistent in regard to the patient 
inclusion criteria and HLA typing methodology (Keller, 1994; Smith, 
2005; Underhill et al., 2001; Helbig et al., 2003; Ortega-Hernandez 
et al., 1173; Pasi, 2011), and reproducible associations are lacking. In 
the largest study (N = 110), prior to our previous study, the most sig-
nificant association was with the serologically defined HLA-DQ3 (OR =
1.8, 95% CI 1.2–2.8) (Keller, 1994). Furthermore, associations with HLA 
alleles HLA-DQA1*01, HLA-DRB1*13:01 and HLA-DQB1*06:02 have 
also been reported (Smith, 2005; Carlo-Stella et al., 2009; Spitzer and 
Broadman, 2010). Most of these studies incorporate<50 patients and are 
therefore statistically underpowered for detecting associations of mod-
erate effect size. 
In our previous study by Lande (2020), we found a significant ME/ 
CFS association with HLA-DQB1*03:03 and HLA-C*07:04 alleles. A 
subsequent study observed that the presence of either of the two HLA 
risk alleles, HLA-DQB1*03:03 and HLA-C*07:04, appeared to be pre-
dictive for response to cyclophosphamide (Rekeland et al., 2020). The 
original study by Lande et al. could not determine if the observed HLA 
associations were due to LD with another locus in the MHC, since it only 
investigated six of the classical HLA loci across this immunologically 
important, gene dense and polymorphic region. 
The current study therefore aimed to fine map the HLA association 
signals in ME/CFS. To this end, we included genotyping of five addi-
tional classical HLA loci and 5,342 SNPs using 427 Norwegian ME/CFS 
cases and 480 controls. To our knowledge, this is the first study 
comprehensively investigating the association between the MHC and 
ME/CFS. 
2. Material and methods 
2.1. Study population 
A total of 427 Norwegian ME/CFS patients and 480 healthy, ethni-
cally matched controls were included in this study. All, but four, patients 
were diagnosed according to the 2003 Canadian Consensus Criteria 
(Carruthers et al., 2003). The total patient cohort was recruited from 
four separate inclusion groups; 1) the rituximab studies (Fluge, 2011; 
Fluge et al., 2019), 2) the cyclophosphamide study (Rekeland et al., 
2020), 3) the CFS/ME biobank at Oslo University Hospital and 4) pa-
tients recruited via announcements in patient networks. Overlapping 
patients from the inclusion groups have been excluded as well as pa-
tients with self-reported non-Norwegian/Scandinavian ancestry. We 
included 38 patients from the cyclophosphamide study (two were 
excluded due to non-Norwegian ancestry), and tested the fine mapped 
HLA risk variants against the clinical response to cyclophosphamide. 
2.2. SNP and HLA genotyping 
SNPs were genotyped using the Infinium ImmunoArray-24 v2 
BeadChip (iChip v2) from Illumina (Illumina, San Diego, USA) for the 
427 cases, while the 480 healthy controls were genotyped using 
HumanImmuno-v1 BeadChip (iChip v1, Illumina), as described previ-
ously (Beecham, 2013). The data were merged using Plink v1.9. Sub-
sequently, the SNPs from the MHC region on chromosome 6 (29.6–33.1 
Mb, build 37) were extracted. 
High resolution, targeted, next generation sequencing (NGS) of HLA 
class I and II genes was performed for the 427 ME/CFS patients by Lande 
et al. using NGSgo kit and NGSengine software (Gendx, Utrecht, the 
Netherlands) (Lande, 2020), with 3 samples being omitted due to lack of 
DNA and 4 additional samples being recruited to the current study. Five 
additional HLA loci (DQA1, DPA1, DRB3, DRB4, DRB5) were included in 
the current study. HLA genotyping for the 480 healthy controls was 
performed by NGS at Stanford University, USA (Creary, 2021), and not 
part of the paper by Lande (2020). Thus, all the 11 classical HLA genes 
HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, -DPA1, -DRB3, -DRB4 and 
-DRB5 were included in this study. Due to 1% missing genotypes for 
some of the HLA genes, HLA imputation was conducted to add to the 
observed HLA genotypes. To assess the precision of the imputation re-
sults, we compared imputed vs. known HLA genotypes at 2-field reso-
lution for the entire dataset which showed an overall concordance of 
around 99.8%. 
2.3. Quality control and statistical analysis 
Genotyping cluster-plots from iChip v2 were manually inspected and 
poor performing SNPs were excluded prior to further analyses. SNPs 
with low genotyping success rate (<99%) and minor allele frequency 
(<1%) were excluded. Likewise, SNPs deviating from Hardy Weinberg 
equilibrium (p < 0.001) in controls were excluded. Only successfully 
genotyped SNPs overlapping the iChip v1 and v2 were analyzed. A grand 
total of 5,342 SNPs passed quality control and were included in the 
analyses. For SNP imputation, the Michigan imputation server was used 
(Reference Panel: 1000G Phase 3v5 EUR, rsq filter R < 0.3, phasing via 
Eagle v2.4, Build 37) (Das et al., 2016), while HLA*IMP:03 was used for 
the subsequent HLA imputation (Motyer, 2016). 
BIGDAWG package v 2.1 in R (Pappas et al., 2016) was used for 
initial amino acid analysis. Association analyses were otherwise per-
formed using Unphased v 3.0.13 (Dudbridge, 2008). Amino acid calls to 
be included in association analyses using Unphased were based on 
codon information from the reference sequences in the IPD-IMGT/HLA 
database for the alleles and annotated as biallelic markers (present or 
not present). For LD plots, Haploview version 4.2 was used. Locuszoom 
was used to make plots visualizing association results with combined LD 
measures from publicly available 1000G EUR data (Pruim et al., 2010). 
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The Fisher’s exact probability calculator, MedCalc was also used. 
In this study, we used a significance threshold of p ≤ 0.001, and a 
suggestive threshold of p < 0.005. This is primarily based on the pre-
viously observed significance levels of the HLA association in Lande 
(2020). At present time, genomic research in ME/CFS lacks large cohorts 
diagnosed according to the Canadian Consensus Criteria able to detect 
GWAS level significance. 
2.4. Bioinformatic databases 
The GTEx database was used to interrogate whether the associated 
SNPs could serve as expression quantitative trait loci (eQTL) by influ-
encing the gene expression in various tissues. The data used for the 
analyses described in this manuscript were obtained from single tissue 
eQTL using the GTEx Portal on 05/20/21. The human protein atlas was 
used to obtain data on protein and gene expression for specific genes in 
various tissues (Uhlén, 2015). 
3. Results 
Among the genotyped SNPs across the extended MHC on chromo-
some 6 (29.6–33.1 Mb, build 37), 5,342 SNPs passed quality control and 
were used in the subsequent analyses. In addition, our dataset comprised 
of 222 classical 2-field HLA alleles from the 11 classical HLA genes, and 
789 amino acids encoded by the HLA alleles were also tested. 
3.1. Several ME/CFS associations across the MHC 
Association analyses identified 60 associated markers (p ≤ 0.001) 
across the MHC, including the HLA class I and II regions (Figure 1; 
Supplementary Table 1). None of the classical HLA loci or alleles 
reached the significance threshold of p ≤ 0.001 (Supplementary 
Table 2). The class II gene, HLA-DQB1, was the most associated HLA 
locus displaying a p-value (p = 0.004) below the suggestive threshold (p 
< 0.005). Interestingly, HLA-DQB1 amino acid residues 57D and 57A 
did however reach the significance threshold of p ≤ 0.001 (p = 0.001, 
both). Allele-wise, only the HLA class I allele HLA-C*07:04 (p = 0.004) 
showed suggestive association. Five SNPs marked the distinct regions 
associated with ME/CFS (p ≤ 0.001), i.e. from telomeric to centromeric: 
rs9366658 in the extended class I region (risk allele frequency (RAF) =
86.7% in cases vs 80.0% in controls; OR = 1.6; p = 0.0003), three SNPs 
in the HLA class I region namely rs388234 (RAF = 42.8% in cases vs 
35.2% in controls; OR = 1.4; p = 0.0008), rs4711249, (RAF = 18.7% in 
cases vs 12.8% in controls; OR = 1.6; p = 0.0005) and rs3130477 (RAF 
= 90.6% in cases vs 85.6% in controls; OR = 1.6; p = 0.0008), and 
finally rs9275582 in the HLA class II region (RAF = 78.3% in cases vs 
70.6% in controls; OR = 1.5; p = 0.0002). 
Repeated analyses including the imputed SNP genotypes did not 
reveal any additional regions, but rather provided additional significant 
SNPs supporting the already observed association signals (Supplemen-
tary Fig. S1). 
3.2. HLA class I and II regions are independently associated 
Given the complex and extensive LD structure of the MHC, we next 
investigated the dependencies between the five tag SNPs of which one is 
located in the extended HLA class I region (rs9366658), three in the HLA 
class I region (rs388234, rs4711249, rs3130477), and one in the HLA 
class II region (rs9275582). 
Overall, the five SNPs showed low correlation measured by r2 < 0.15 
(Figure 2 A and B), however, some haplotype structures were indicated 
from the higher D’ values (Figure 2 C and D). Therefore, to further 
explore the dependency between the SNP associations, we performed 
conditional association analyses for each of the five SNPs separately. The 
class II SNP, rs9275582, remained significantly associated (p < 0.0004, 
Table 1) regardless of which of the other tag SNPs that was conditioned 
for, and likewise conditioning on rs9275582 did not affect the associa-
tion signals seen for the four other SNPs (p ≤ 0.001). 
Contrary to this, the dependencies between the extended class I/class 
I SNPs (rs9366658, rs388234, rs4711249, and rs3130477) were less 
clear. The significance of the SNP associations were generally weakened 
after conditional analyses (Table 1). Interestingly, rs9366658 remained 
significantly associated (p = 0.0009) after conditioning on rs4711249, 
and likewise rs4711249 remained associated after conditioning on 
rs3130477 (p = 0.0003). Haplotype analyses between the telomeric SNP 
(rs9366658) in the extended class I region and the class I SNP 
(rs388234) showed significant association for those carrying either the 
risk alleles (p = 0.0002) or non-risk alleles (p = 0.00004) at both loci 
(Supplementary Table 3). However, the most common haplotype seen in 
the population (>45%) carried the risk allele at rs9366658 and the non- 
Fig. 1. Single marker association results across the major histocompatibility complex (MHC) in 427 Norwegian Myalgic encephalomyelitis/Chronic fatigue syndrome 
(ME/CFS) patients and 480 healthy controls. The statistical significance of the association analysis as -log10 of the P-value (y-axis), is plotted against the position on 
chromosome 6 shown in base pairs (bp, x-axis). The black, horizontal dashed line represents a significance threshold of P = 0.001, while the grey dashed line 
represents the suggestive threshold of P = 0.005. Association results are colored according to single nucleotide polymorphisms (SNPs), allelic HLA-C and -DQB1 
analyses (HLA allelic), HLA amino acid analyses and HLA locus-wise analyses. Positions are according to National Center for Biotechnology Information’s build 37 
(hg19). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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risk allele at rs388234, without being ME/CFS associated (p = 0.5). Only 
few haplotypes (<5%) carried the risk allele only at rs388234. Hence, 
rs9366658 appears to be secondarily associated and hitch-hiking on 
rs388234. A similar pattern was seen for the pairwise haplotype analysis 
between rs4711249 and rs3130477. The haplotype with risk alleles at 
both SNPs was positively associated (p = 0.0002), while the non-risk 
alleles were carried on a negatively associated haplotype (p = 0.001). 
The most common haplotype (>70%) carried the risk allele at 
rs3130477 but was not significantly associated (p = 0.5). Few 
haplotypes (<1%) only carried the risk allele at rs4711249. 
Taken together, based on the SNP associations, we found three 
apparently independent association signals, best captured by the tag 
SNPs: rs388234 and rs4711249 in the HLA class I region and rs9275582 
in the HLA class II region. 
Fig. 2. Linkage disequilibrium (LD) plot for the five tag SNPs rs9366658, rs388234, rs4711249, rs3130477 and rs9275582 measured by r2 in cases (A) and controls 
(B), and by D’ in cases (C) and controls (D) for 427 Norwegian ME/CFS patients and 480 healthy controls. Values shown in the figures are 100 × r2 (A and B) and 100 
× D’ (C and D). 
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3.3. The relation between the ME/CFS associated tag SNPs and HLA-C 
and HLA-DQB1 
We next addressed the relationship between these new SNP associ-
ations with our previously reported ME/CFS associations with HLA-C 
(C*07:04) and HLA-DQB1 (DQB1*03:03). After conditioning on HLA-C, 
several SNP associations were still evident in the four initial association 
peaks (Figure 3A), including for rs388234 (p = 0.0005), telomeric of 
HLA-A. The SNP closest to HLA-C, rs4711249, did not remain associated 
after conditioning on HLA-C (p = 0.21), however, several other SNPs in 
the same LD region still showed strong association, e.g. rs7766094 (p =
0.0001), an intronic SNP in VARS2, annotated as splice donor variant. 
Table 1 
Conditional analyses to explore the dependencies between the most significant SNPs tagging the five associated regions. BP is the position at chromosome 6 and P is P 
values for the unconditioned single marker association analysis.     
P values after conditioning on following SNP 
SNP BP P rs9366658 rs388234 rs4711249 rs3130477 rs9275582 
rs9366658 26469866  0.0003 1 0.002 0.0009 0.009 0.0002 
rs388234 29533295  0.0008 0.02 1 0.003 0.005 0.001 
rs4711249 30908266  0.0005 0.004 0.002 1 0.0003 0.001 
rs3130477 31428920  0.0009 0.06 0.005 0.03 1 0.0006 
rs9275582 32680070  0.0002 0.0004 0.0002 0.0003 0.00007 1  
Fig. 3. Single marker association results within the major histocompatibility complex (MHC) in Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) 
patients and healthy controls for analyses conditioning on A) HLA-C and B) HLA-DQB1. The statistical significance of the association analysis as -log10 of the P-value 
(y-axis), is plotted against the positions on chromosome 6 shown in base pairs (bp, x-axis). The black, horizontal dashed line represents a significance threshold of P 
= 0.001. Association results are colored according to single nucleotide polymorphisms (SNPs), allelic HLA-C and -DQB1 analyses (HLA allelic), HLA amino acid 
analyses, HLA locus-wise analyses and tag SNPs. Positions are according to National Center for Biotechnology Information’s build 37 (hg19). (For interpretation of 
the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Interestingly, HLA-C*07:04 was almost always carried together with the 
risk allele at rs4711249 on a high-risk haplotype (3.3% in cases vs 1.3 % 
in controls; p = 0.001). However, the SNP risk allele was also carried on 
other HLA-C alleles (Supplementary Table 4), and overall haplotypes 
comprising the rs4711249 risk allele together with non-C*07:04 is still 
predisposing (15.4% in cases vs 11.5% in controls; p = 0.01). 
Conditioning on HLA-DQB1, reduced the SNP associations below our 
significance threshold (Figure 3B), except for the class I associated SNP, 
rs4711249. 
3.4. Closing in on the primary association in the HLA class I region 
The SNP rs4711249 showed the most significant (p = 0.0005) as-
sociation within the HLA class I region and is situated close to the SFTA2 
and DPCR1 genes and almost 33 kb downstream of HLA-C. rs4711249 is 
in strong LD with several SNPs spanning the genes DDR1, MIR4640, 
GTF2H4, VARS2, SFTA2 and DPCR1 (Figure 4A). The expression levels 
of these genes differed significantly according to the genotype present at 
rs4711249 in multiple tissues (Supplementary Fig. 2). In general, the 
risk allele A was for most eQTLs associated with increased gene 
expression (i.e. DDR1, VARS2, and SFTA2), but also with decreased 
expression (i.e. GTF2H4, SFTA2 and DPCR1). Interestingly, rs4711249 
influences the gene expression in relevant tissues for ME/CFS, like 
nerves (DDR1, SFTA2, DPCR1), brain (GTF2H4), muscle (GTF2H4, 
VARS2) and blood (DDR1, VARS2). 
The other associated SNP in the HLA class I region, rs388234 (p =
0.0008), is located in intron 18 of an alternative splice variant of the 
GABBR1 gene (ENST00000355973.7). No strong LD with surrounding 
SNPs was observed (Figure 4B). No expression quantitative trait was 
observed for rs388234 and full length GABBR1 (data not shown). The 
human protein atlas reveals that GABBR1 is mainly expressed in brain, 
including in cerebellum, cerebral cortex and hippocampus (Supple-
mentary Fig. 3). Notably, rs388234 lacks association support by sur-
rounding SNPs, and the signal disappeared after conditioning on HLA- 
DQB1 (Figure 3B). 
Fig. 4. The significance of the association signals from all SNPs, including their LD with the top SNP, across the disease susceptibility regions tagged by A) 
rs4711249, B) rs388234 and C) HLA-DQB1. The significance of the association signals, -log10P-value (y-axis), are plotted against the positions on chromosome 6 
shown in base pairs (bp, x-axis). The colour of the dots is indicating r2 value. (For interpretation of the references to colour in this figure legend, the reader is referred 
to the web version of this article.) 
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3.5. HLA-DQB1 could be primarily associated with disease risk by amino 
acid 57 
In the HLA class II region, the rs9275582 was the most significantly 
associated SNP (p = 0.0002). Rs9275582 is located upstream of both 
HLA-DQB1 and -DQA2 and is in strong LD with surrounding SNPs 
(Figure 4C). Notably, the SNP density is very low across the HLA –DR 
and -DQ loci. The HLA-DQB1 association was best captured by the amino 
acid position 57 (57D: OR = 1.36, p = 0.001 and 57A: OR = 0.7, p =
0.001). Both amino acid 57A and 57D are present at multiple HLA-DQB1 
alleles covered by our HLA genotyping (Table 2). Albeit none of the 
alleles show significant association per se, the alleles comprising 57D are 
generally increased among ME/CFS patients, while the 57A encoding 
alleles are increased among controls. After conditioning on residue 57A, 
the significance of rs9275582 dropped below our significance level (p =
0.004) and likewise after conditioning for 57D (p = 0.03). Furthermore, 
after adjusting for the whole HLA-DQB1 locus, no residual association 
remained (p = 0.99, Figure 3B). Similarly, conditioning on rs9275582 
abolished the association for the HLA-DQB1 amino acids 57A (p = 0.03) 
and 57D (p = 0.2). Accordingly, the rs9275582 risk allele shows strong 
positive LD (measured by D’) with all common HLA-DQB1 alleles (>5%) 
encoding for the amino acid position 57D and strong negative LD (D’=- 
1) with the HLA-DQB1*03:02 allele encoding the amino acid 57A 
(Supplementary Table 5). 
3.6. Risk variants in relation to cyclophosphamide treatment response 
We have previously reported that the HLA risk alleles DQB1*03:03 
and C*07:04 are associated with response to cyclophosphamide treat-
ment in ME/CFS patients (Rekeland et al., 2020). Notably, HLA-DQB1 
57D was carried by almost all patients (94.7%) and hence was not 
useful in discriminating responders from non-responders. Since the most 
pronounced association in the class I region in the current study maps 
outside HLA-C, we investigated the rs4711249 risk allele against 
cyclophosphamide treatment response in 38 individuals. In total 39.5% 
(15 out of 38) of the patients from the cyclophosphamide study carried 
either the rs4711249 risk allele and/or DQB1*03:03. Interestingly, 61.9 
% (13 out of 21) of responders to cyclophosphamide carried either the 
rs4711249 risk allele and/or DQB1*03:03 vs 11.8% (2 out of 17) of non- 
responders. A similar trend was observed for patients having HLA- 
C*07:04 and/or DQB1*03:03 (81.8 % or 9 out of 11 patients carrying the 
alleles vs. 44.4% or 12 out of 27 non-carriers were responders). 
4. Discussion 
By combining high-quality HLA genotyping and SNP genotyping 
data in unconditional and conditional analyses, we showed that there 
are independent associations with HLA class I and class II region in ME/ 
CFS. 
Association with HLA genes within the MHC is a hallmark for 
immune-mediated diseases. However, to pinpoint the primary associa-
tions can be challenging due to the complex underlying LD and haplo-
type structures. In the recent study by our group, we found ME/CFS 
associations with the HLA-C*07:04 and HLA-DQB1*03:03 alleles when 
investigating 6 of the 11 classical HLA genes (Lande, 2020). In the 
current study, we investigated all 11 classical HLA genes in combination 
with 5,342 SNPs. 
We initially identified several potentially associated regions across 
the extended MHC tagged by five SNPs. However, several of these 
appeared to be secondary due to LD and extended haplotype structures, 
leaving two associated regions in the HLA class I region and one in the 
HLA class II region. Furthermore, after scrutinizing the relationship 
between the association signals through LD, conditional and haplotype 
analyses, we observed that HLA class I and II were independently 
associated with ME/CFS. 
The most pronounced association in the HLA class I region was with 
rs4711249. This SNP is most likely not reflecting an association with 
HLA-C. Interestingly, the association between HLA risk alleles for ME/ 
CFS and cyclophosphamide response was maintained even if we 
replaced the HLA-C*07:04 allele with the risk allele at rs4711249. 
However, due to complex LD patterns, it is difficult to conclude that the 
association maps outside the classical HLA locus, however, the 
numerous associated SNPs tagged by rs4711249 spans several genes 
(DDR1, GTF2H4, VARS2, SFTA2 and DPCR1) being candidates for 
involvement in ME/CFS. Interestingly, rs4711249 genotype was asso-
ciated with gene expression differences of these surrounding genes in 
both muscle, brain, blood and nervous tissue. Hence, the risk variant 
could be a regulatory variant that provide susceptibility to ME/CFS 
through altering gene expression levels. The VARS2 gene is implicated in 
several mitochondrial diseases with causative mutations reported for 
mitochondrial encephalopathy and putative pathogenic variants have 
been found for mitochondrial respiratory complex deficiencies (Diodato 
et al., 2014; Taylor et al., 2014). This is interesting given the clinical 
manifestations of ME/CFS and the proposed, but not yet established, 
alterations of mitochondrial respiratory function related to ME/CFS 
(Holden, 2020). 
The other HLA class I association, rs388234, is located in an alter-
native intron of a splice variant of the GABBR1 gene. Unlike rs4711249, 
we did not observe eQTLs for rs388234 and full length GABBR1. How-
ever, the human protein atlas shows that GABBR1 is mainly expressed in 
the brain. The GABBR1 gene encodes a receptor for gamma- 
aminobutyric acid (GABA), which is the main inhibitory neurotrans-
mitter in the mammalian central nervous system. Changes in this gene 
may underlie brain disorders and may be involved in regulating prolif-
eration of hematopoietic stem cells (Xi et al., 2011; Elujoba-Bridenstine, 
et al., 2019). The robustness of the association with rs388234 is weak, as 
the signal is not supported by any surrounding SNPs, and the rs388234 
association disappeared after conditioning on HLA-DQB1. 
Additionally, for the HLA class II region, our analyses point towards 
the main association signal being within the HLA-DQ locus. However, 
we could not determine whether rs9275582 or HLA-DQB1 represent the 
primary association due to strong LD. 
Lande et al. found HLA-DQB1*03:03 to be associated with risk of 
ME/CFS, and we observed the same trend, albeit not significant, for the 
same HLA-DQB1 allele (6.4% vs 4.7%, OR = 1.66) with our smaller and 
distinct control data set. However, it seems likely that if HLA-DQB1 is 
the main class II risk locus, it is not conferred by one specific allele, but 
rather an amino acid position as we observe significant association with 
amino acid residue 57D which is coded by HLA-DQB1*03:03 and several 
Table 2 
Association between ME/CFS and amino acid D or A in position 57 of DQB1, and 
their respective HLA-DQB1 alleles.   





Residue 57 aspartic acid 
(57D) 
53.6 46.0 0.001 
Alleles encoding 57D:    
DQB1*03:01 15.0 13.3 0.3 
DQB1*03:03 6.4 4.7 0.1 
DQB1*03:09 0 0.1 1 
DQB1*03:19 0.1 0 0.5 
DQB1*04:02 4.6 4.2 0.7 
DQB1*05:03 2.8 1.8 0.1 
DQB1*06:01 0 0.5 0.06 
DQB1*06:02 17.0 14.9 0.2 
DQB1*06:03 7.7 6.5 0.3 
DQB1*06:16 0 0.1 1  
Residue 57 alanine (57A) 28.8 35.9 0.001 
Alleles encoding 57A:    
DQB1*02:01 11.4 13.8 0.1 
DQB1*02:02 5.3 5.7 0.7 
DQB1*03:02 12.1 16.4 0.009 
DQB1*03:04 0.1 0.1 1  
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other alleles. In fact, none of the alleles coding for amino acid residue 
57D showed any significant associations at the allelic level, thus illus-
trating the need for multi-level analysis of HLA. The HLA-DQB1 residue 
57 has been implicated in immune-mediated disease previously, i.e. in 
type 1 diabetes where 57A confers susceptibility while 57D provides 
protection (Gough and Simmonds, 2007; Holoshitz, 2010). This amino 
acid is a crucial residue in the peptide-binding groove of HLA-DQB1 
involved in antigen presentation and T cell receptor interaction. The 
presence of different amino acids at this residue could possibly modulate 
the stability of the molecule thereby influencing the binding of peptides 
(Gough and Simmonds, 2007). 
In most diseases, it has been difficult to identify the main genetic 
determinants in the MHC region (Fiorillo et al., 2017). Strong LD, the 
density of immune related genes, and the additive effect of multiple HLA 
loci are all key factors. Unfortunately, few HLA studies have been un-
dertaken in ME/CFS, and overall, they lack statistical power, strict 
diagnostic criteria for ME/CFS, high resolution HLA genotypes and fine 
mapping using markers spanning the MHC. Hence, our work marks, to 
the best of our knowledge, the first thorough and rigorous HLA analysis 
and fine mapping in ME/CFS. The strength of our study is the dense 
genetic map including deep sequencing of 11 classical HLA genes and 
ME/CFS patients diagnosed according to the strict Canadian criteria. 
Nevertheless, it must be acknowledged that we are, despite having 4–10 
times as many patients as previous studies, still lacking statistical power. 
Consequently, we used a significance threshold of p ≤ 0.001 without 
correcting for multiple testing. In established autoimmune diseases, 
albeit the initials studies only comprised of hundreds of patients, the 
genetic determinants in the MHC region have now been fine mapped in 
several thousand patients. In addition, we have, to the best of our ability, 
tried to incorporate homogeneously diagnosed patients as well as the 
use of best practice and QC in data analysis. The statistical power issue 
will hopefully be addressed in future studies given the growing coop-
eration between groups, and the on-going collection of DNA from ME/ 
CFS patients, like the DecodeME project (www.decodeme.org.uk). This 
will enable further studies of larger and more powerful cohorts, which 
are warranted to firmly establish the involvement of the MHC and HLA 
genes in ME/CFS. 
In addition, the COVID-19 pandemic might increase the number of 
people who develop ME/CFS given the substantial overlap between ME/ 
CFS and post COVID syndrome (Komaroff and Lipkin, 2021). The 
commonalties between the two diseases could possibly reveal similar 
HLA predispositions which might lead to better understanding of both 
pathologies. 
In conclusion, we report, to the best of our knowledge, the first HLA 
fine mapping study in ME/CFS, in an attempt to address a putative 
immunologic component of the ME/CFS pathogenesis. We observed 
independent association signals from the HLA class I and class II regions, 
which encourage future genetic studies of the MHC in ME/CFS. 
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